Abstract
Members of the virus family Picornaviridae are ubiquitous in nature and responsible for a broad spectrum of clinical syndromes ranging from the common cold to neonatal en-teroviral sepsis. The two genuses of classification of picornaviridae are the enteroviridae and rhinoviridae. Rhinoviruses express human parisitization clinically as a naso-pharyngeal syndrome (the “common cold”) which occurs in all populations and age groups and can take up to two weeks to resolve. Exceptions to the uncomplicated course of rhinovirus nasopharyngeal infection include special patient sets at risk for infectious complications including patients with asthma, congestive heart failure, bronchiectasis and cystic fibrosis.1 In contrast, the pathology of enterovirus disease in humans relies principally upon the somatotopic localization of infection after primary replication in the gastrointestinal tract and subsequent bloodborne dissemination.2 Myocarditis, meningitis, encephalitis, respiratory syndromes (ranging from nasopharyngitis to lobar pneumonia), and mucocutaneous manifestations such as hand, foot and mouth disease and herpangina characterize the multifaceted presentations of enterovirus disease in humans.3 The absence of precise localization of seeded bloodborne infection by enterovirus may eventuate in an ill-defined “transition” syndrome characterized by fever, malaise, myalgias, headache and mild respiratory complaints, often referred to as “summer flu”, given the predilection of enteroviruses to express disease during the summer and early fall months. The high prevalence of asymptomatic or mildly symptomatic infections has led to the analogy of the human populations representing an ‘ocean’ of enterovirus infections, with ‘islands’ in the ocean representing discrete and well recognized organ-specific clinically expressed syndromes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gwaltney GM, Ruckert RR. Rhinovirus. DD Richman, RJ Whitley and FG Hayden (ed.) Clinical Virology. Churchill Livingstone. New York. 1997; 1025–1047.
Rotbart HA.. Enteroviruses. DD Richman, RJ Whitley and FG Hayden (ed.) Clinical Virology. Churchill Livingstone. New York. 1997; 997–1023.
Rotbart HA (ed.) Human Enterovirus Infections. ASM Press. Washington, D.C.1994.
McKinlay MA, Pevear DC, Rossmann MG. Treatment of the Picornavirus common cold by inhibitors of viral uncoating and attachment. Annual Reviews of Microbiology 1992; 46: 635–654.
Smith TJ, Kremer MJ, Luo M, et al. The site of attachment of human rhinovirus 14 and antiviral agents that inhibit uncoating. Science. 1986; 233: 1286–1293.
Diana GD, Pevear DC. Antipicornavirus drugs: current status. Antiviral Chemistry and Chemotherapy. 1997; 8: 412–418.
O’ Connell J, Albin A, Blum D, et al. Development of antiviral agents for Picornavirus infections. In HA Rotbart (ed.) Human Enterovirus Infections. ASM Press. Washington, DC. 1995; 419–434.
Hayden FG, Andries A, Janssen PAJ. Safety and efficacy of oral pirodavir (R 77975) in experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy. 1992; 36: 727–732.
Schiff GM, Sherwood JR, Young EC, et al. Prophylactic efficacy of WIN 54954 in prevention of experimental human Coxsackievirus A21 infection and illness. Antiviral Research. 1992; 17(Suppl 1): 92.
Turner RB, Dutko FJ, Goldstein NH, et al. Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy. 1993; 37: 297–300.
Diana GD, Rudewicz P, Pevear DC, et al. Picornavirus inhibitors: triflouromethyl substitution provides a global protective effect against hepatic metabolism. Journal of Medicinal Chemistry 1995; 38: 1355–1371.
Rotbart HA, Brennan PJ, Fife KH, et al. Enterovirus meningitis in adults. Clinical Infectious Diseases. 1998; 27(4) (in press).
Rotbart HA. Enteroviral infections of the central nervous system. Clinical Infectious Diseases. 1995; 20: 971–981.
Elmore, JG, Horwitz, RI, Quagliarello, VJ. Acute Meningitis With a Negative Gram’ s Stain: Clinical and Management Outcomes in 171 Episodes. The American Journal of Medicine. 1996; 100: 78–84.
Rice, SK, Heinl, RE, Thornton, et al. Clinical Characteristics, Management Strategies, and Cost Implications of a Statewide Outbreak of Enterovirus Meningitis. Clinical Infectious Diseases. 1995; 20: 931–937.
Pevear DC, Scipel ME, Pallansch MA. In vitro activity of VP 63843 against field isolates of non-polio en-teroviruses. H-99 Accepted for presentation at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA September 15-18, 1996
Groarke JM and Pevear DC. Attenuated virulence of pleconaril-resistent Coxsackievirus B3 variants, (submitted for publication).
Kearns GL. Pharmacokinetics of pleconaril in adults. Abstract H-21. Accepted for presentation at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA September 27-October 1, 1997
Kearns GL, Wells TG et al. Pharmacokinetics of pleconaril in children. Abstract A-206. Accepted for presentation at the 99th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics. New Orleans, LA March 30-April 1, 1998.
Schiff GM et al. Oral efficacy of VP 63843 in Coxsackievirus A21 infected volunteers (Abstract H42). Accepted for presentation at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. September 15-18, 1996.
Couch RB, Knight VR, Gerone PR, et al. Factors influencing response of volunteers to inoculation with Coxsackievirus A type 21. American Review of Respiratory Disease. 1969; 99: 34–69.
Couch RB, Cate TR, Gerone PJ, et al. Production of illness with a small-particle aerosol of Coxsackie A21. Journal of Clinical Investigation. 1965; 44: 535–542.
Weiner LB, Rotbart HA, Gilbert DL, et al. Treatment of enterovirus meningitis with pleconaril (VP 63843) an antipiconaviral agent. Accepted for presentation at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
McKinney RA, Katz SL, Wilfert KM. Chronic enteroviral meningoencephalitis in agammagolbulinemic patients. Reviews of Infectious Diseases. 1987; 9: 334–356.
Webster ADB, Rotbart HA, Warner T, et al. Diaignosis of enterovirus brain disease in hypogammaglobu-linemic patients by polymerase chain reaction. Clinical Infectious Diseases. 1993; 17: 657–661.
Rotbart HA, Jones A, Novelli V, et al. Pleconaril treatment of chronic enteroviral central nervous system infections in children with agammaglobulinemia. Accepted for presentation at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
Sokhandan, M, et al. The contribution of respiratory viruses to severe exacerbations of asthma in adults. Chest. 1995; 107: 1570–1575.
Sung BS, Chonmaitree T, Broemeling LD, et al. Association of rhinovirus infection with poor bacteriologic outcome of bacterial viral Otitis media. Clinical Infectious Diseases. 1993; 17: 38–42.
Pitkaranta A, Virolainen A, Jero J, et al. Detection of rhinovirus, respiratory syncytial virus, and Coronavirus infections in acute Otitis media by reverse transcriptase polymerase chain reaction. Pediatrics. 1998; 102: 291–295.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rogers, J.M., Diana, G.D., McKinlay, M.A. (1999). Pleconaril. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 5. Advances in Experimental Medicine and Biology, vol 458. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4743-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4743-3_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7150-2
Online ISBN: 978-1-4615-4743-3
eBook Packages: Springer Book Archive